# Proof of Confidence Study of CCR2 Antagonist (BMS-741672) in Insulin Resistance

> **NCT00699790** · PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 58 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** CCR2 Antagonist
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00699790
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-02
- **Primary completion:** 2009-12
- **Final completion:** 2009-12
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2015-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00699790

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00699790, "Proof of Confidence Study of CCR2 Antagonist (BMS-741672) in Insulin Resistance". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00699790. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*